Innovative Drug Discovery and Nanotechnology
(Track)
A New Approach to the Design and Synthesis of Drugs Based on Self-Organizing Quasi-Life Systems
Sonya Sophya Farber
Department of Drug Design and Nanotechnology, American Medical Technologies, Inc., USA
Abstract:
Statistical data on introducing these drugs, as well as a number of low-molecular drugs, on the market demonstrate that they are insignificantly more effective than a placebo. The effec-tiveness of amlodipin at the third stage of clinical tests was only 22% higher than that of the pla-cebo (amlodipin: 52%; placebo: 30%). The reasons that a drug might turn out to be ineffective or of little effect for 48% of patients have not yet been determined. The FDA's depressing statistics on the third stage of clinical tests of drugs demonstrate the low effectiveness of practically all medicinal drugs available on the pharmaceutical market. At present, more and more scientists are tending to believe that receptors differ in much the same way as do human faces, even within a single species. This hypothesis provides a good explanation for drugs' low levels of effectiveness. A conservative structure of a classical drug (like one "key") cannot match a specific receptor ("many different, though similar, locks") in all individuals of one species equally and with equal affinity. To provide the maximum affinity for the maximum number of people, it is necessary to have a mixture of millions of molecules that are very similar but still different from each other in one vial. In this case we obtain not one "key," but a whole bunch of keys. At least one "key" from this "bunch" will match a specific patient and his/her original receptor. If it is impracticable under modern conditions to synthesize a specific inhibitor for a specific patient, then the only option is to produce millions of inhibitor isoforms in one mole of substance. One of the most reasonable methods of solving the problem of low drug effectiveness is to obtain precision partially chemically modified recombinant biotechnological preparations: biopolymers and their semicomplete hydrolyzates. The usage of this technology will bring pharmaceutical science to a level of intensive development, make molecular modeling methods much simpler, and increase the probability of a practical means of introducing therapeutic drugs. The effectiveness of this design method (drug design) for medications is confirmed by the effectiveness of the antiviral veterinary drug Albuvir, which was designed and implemented on the basis of self-organizing quasi-life systems. This drug is effective in the treatment of nearly all existing viral infections in animals, even at very severe stages of the disease, with quick therapeutic manifestation. This drug has received permission for production and application as a veterinary medicine. A second drug, Anticanum, is a self-organizing quasi-life system based on modified RNA. It has the properties of microRNA and has shown significant cytostatic properties on more than 50 cell cultures and in three animal models. Research in the area of substituting dynamic medications for conservative structures continues.
